Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Opinion & Analysis (NDAQ:BCRX)

The Calandra Report: Blood in streets, rivers of fortune

Thom Calandra July 24, 2015

The Calandra Report: Rapivab, MERS, Thailand & BCRX

Thom Calandra June 19, 2015

The Calandra Report: Show me a favorite, I dare you

Thom Calandra June 8, 2015

The Calandra Report: Moveable feast of pharma, not gold

Thom Calandra June 4, 2015

The Calandra Report: They're jamming In the name of the lode

Thom Calandra March 13, 2015

Ultra-Actionables: Natcore Tech, Angkor Gold, BioCryst, Vegas

Thom Calandra February 20, 2015

The Calandra Report: Author sees 10% death rattle for big stocks

Thom Calandra January 27, 2015

The Calandra Report: X-Factor stocks

Thom Calandra December 30, 2014

Thom's big stake In Cambodia gets bigger

Thom Calandra December 8, 2014

Le Plus TCR En Route: More On Way

Thom Calandra December 5, 2014

The Calandra Report: Thom teaches papaya, plus blazing coconuts, Gemma’s gems and Asia

Thom Calandra November 21, 2014

The Calandra Report: Food for thought... Biocryst, Sysorex

Thom Calandra November 6, 2014

The Calandra Report: Wild Cards, Breeders' Cup In California, Natcore, West Africa

Thom Calandra October 31, 2014

The Calandra Report: Roux New Orleans, parabola on our plates

Thom Calandra October 29, 2014

The Calandra Report: Top choices for fearless investors

Thom Calandra October 21, 2014

The Calandra Report: BioCryst Pharma, nothing to sneeze at

Thom Calandra October 15, 2014

The Calandra Report: Full Moon Promises A National Day For Global Resources

Thom Calandra October 8, 2014

The Calandra Report: The virus that is making resources bearable, just

Thom Calandra October 3, 2014

The Calandra Report: Pat’s Spectacular Now, Colt’s Crossroads

Thom Calandra September 29, 2014

The Calandra Report: Making BioCryst pay

Thom Calandra June 30, 2014